Karolinska Development’s portfolio company Umecrine Cognition presents preclinical Parkinson’s data on golexanolone at AD/PD
06 March 2024 - 7:00PM
UK Regulatory
Karolinska Development’s portfolio company Umecrine Cognition
presents preclinical Parkinson’s data on golexanolone at AD/PD
STOCKHOLM, SWEDEN – March 6, 2024. Karolinska Development AB
(Nasdaq Stockholm: KDEV) today announces that its portfolio company
Umecrine Cognition will present recent nonclinical data elucidating
golexanolone’s mode-of-action in Parkinson’s disease at the
18th International Conference on Alzheimer’s and
Parkinson’s Diseases 2024 in Lisbon, Portugal, during March
5-9.
Parkinson’s disease is a progressive neurodegenerative disease
hallmarked by motor symptoms and disrupted cognitive functions as
well as mental health.
The study that will be presented at the AD/PD conference shows
that golexanolone improves both motor symptoms and non-motor
symptoms, including fatigue, anxiety and depression. Further,
golexanolone was found to partially inhibit the decrease of enzyme
tyrosine hydroxylase and prevent the increase of neurotoxic protein
alpha-synuclein, both key targets in the symptomology of
Parkinson’s disease. The study also showed a decreased activation
of brain immune cells, indicating lowered levels of
neuroinflammation.
“The results further support the proposed mechanism-of-action of
golexanolone also in Parkinson’s disease and exhibits positive
effects on Parkinsonian symptoms and potential for disease
modification, a very promising feature in Umecrine Cognition’s
candidate drug in a field with great medical need,” says Viktor
Drvota, CEO of Karolinska Development.
Umecrine Cognition’s abstract has been accepted for presentation
at the poster session “Alpha-Synucleinopathies, Therapeutic
Targets, Mechanisms for Treatment” on Wednesday, March 6th, as well
as at the oral ePoster presentation, a virtual format for digital
meeting attendees. A representative from Umecrine Cognition’s
scientific collaborator will present the abstract titled:
Golexanolone, a GABA-A receptor-modulating steroid antagonist,
improves fatigue, anxiety, depression and some cognitive and motor
alterations in 6-OHDA rats (abstract #2586).
Karolinska Development's ownership in Umecrine
Cognition amounts to 73 percent.
For further information, please
contact:
Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail:
viktor.drvota@karolinskadevelopment.com
Johan Dighed, General Counsel and Deputy CEO, Karolinska
Development AB
Phone: +46 70 207 48 26, e-mail:
johan.dighed@karolinskadevelopment.com
TO THE EDITORS
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life
sciences investment company. The company focuses on identifying
breakthrough medical innovations in the Nordic region that are
developed by entrepreneurs and leadership teams. The Company
invests in the creation and growth of companies that advance these
assets into commercial products that are designed to make a
difference to patients’ lives while providing an attractive return
on investment to shareholders.
Karolinska Development has access to world-class medical
innovations at the Karolinska Institutet and other leading
universities and research institutes in the Nordic region. The
Company aims to build companies around scientists who are leaders
in their fields, supported by experienced management teams and
advisers, and co-funded by specialist international investors, to
provide the greatest chance of success.
Karolinska Development has a portfolio of eleven companies
targeting opportunities in innovative treatment for
life-threatening or serious debilitating diseases.
The Company is led by an entrepreneurial team of investment
professionals with a proven track record as company builders and
with access to a strong global network.
For more information, please visit
www.karolinskadevelopment.com.
- KD Umecrine Cognition PD data ADPD EN
Karolinska Development Ab (LSE:0P3C)
Historical Stock Chart
From Mar 2024 to Apr 2024
Karolinska Development Ab (LSE:0P3C)
Historical Stock Chart
From Apr 2023 to Apr 2024